Next in the Fight Against COVID-19

*Archived*
Study No Longer Active

Clinical Trial of an Investigational COVID-19 Vaccine for Adults and Teens Over 12

The NextCOVE Study is a Phase 3 clinical trial conducted by Moderna to evaluate an investigational vaccine that may protect people from getting sick if they come into contact with the virus that causes COVID-19, including the XBB.1.5 variant.

About the NextCOVE Study

The NextCOVE Study is evaluating mRNA-1283.815, one of Moderna’s investigational vaccines that may protect people from getting sick if they come into contact with the virus that causes COVID-19. Moderna will be studying this new investigational vaccine in children and adults to learn more about how it works in the body.

You may be able to take part in the NextCOVE mRNA-1283.815 Study if you:

  • Are aged 12-17
  • or Are aged 18+ and have never have had a COVID-19 vaccine
  • Are free from exposure to someone with SARS-CoV-2 infection or COVID-19 within 2 weeks prior to receiving the first vaccination

Receive compensation up to $975 for inconvenience and travel.

*There are additional eligibility requirements, which the trial doctor can explain to you.

You or your child, along with up to 33,574 other individuals, will be helping researchers learn more about Moderna’s latest investigational vaccine that may help protect people from getting sick if they come into contact with the virus.

Complete The Questionnaire Below To Submit Your Information For Future Studies

What to Expect

Participation in the NextCOVE Study will last approximately 13 months and includes up to 7 visits to a trial site and 3 safety phone calls. You or your child will be chosen at random to receive either mRNA-1273.815 or the investigational dose of mRNA-1283.815.

By comparing the vaccines, medical researchers can better understand how well the investigational vaccine works. All trial participants will receive the same level of quality care regardless of which vaccine they receive.

You or your child will also be asked to complete electronic diary (eDiary) entries for the duration of the trial to report any COVID-19 symptoms that may occur. Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.